Healthy Skepticism Library

Items published during the years 2000 to 2009

There are 14385 items in the Healthy Skepticism Library that were published during the years 2000 to 2009.

Page 111 of 144 pages ‹ First  < 109 110 111 112 113 >  Last ›

HSL65
Meier B.
Flawed Device Places F.D.A. Under Scrutiny
The New York Times 2004 Dec 15

HSL70
Safety issue concerns Grassley: The senator sees his probe of the drug approval process as vital to consumers' well-being.
REGISTER WASHINGTON BUREAU 2004 Dec 15

HSL74
Weiss S.
Tauzin Raised Six-Figure Sum from Drug Makers: The New Head of PhRMA Enjoyed the Financial Support of Pharmaceutical Manufacturers While in Congress
Capital Eye 2004 Dec 15

HSL78
Solomon J, Herschaft R.
Woman Died During AIDS Study
The Associated Press 2004 Dec 15

HSL61
Zuger A.
We Love Them. We Hate Them. We Take Them.
The New York Times 2004 Dec 14

HSL58
Herper M.
Face Of The Year: David Graham
2004 Dec 13

HSL60
U.S. Officials Knew of AIDS Drug Risks: Top U.S. Officials Warned of Concerns Before AIDS Drug Sent to Africa
The Associated Press 2004 Dec 13

HSL81
Norton A.
Ads for body-imaging health screens may mislead
Reuters 2004 Dec 13

HSL56
Starr D.
The Cuban Biotech Revolution Embargo or no, Castro's socialist paradise has quietly become a pharmaceutical powerhouse. (They're still working on the capitalism thing.)
Wired Magazine 2004 Dec 12

HSL63
Johnston L.
My wife killed herself because of Prozac, so why is it still being prescribed?
SUNDAY EXPRESS 2004 Dec 12

HSL772
NUPGE hails victory in battle to end drug patent abuse
NUPGE 2004 Dec 12

HSL55
Rowland C.
High-profile ruling near for Maine, drug firms
The Boston Globe 2004 Dec 11

HSL49
Rabin R.
Pill study was wrong: Report touting health benefits from drug's use was flawed, didn't get OK from Women's Health Initiative
Newsday 2004 Dec 10

HSL52
Prozac is risky for children too
BBC News 2004 Dec 10

HSL20051
Arthur I
Cut back drug promotions
Medical Observer 2004 Dec 1019

HSL47
Shipman report demands GMC reform
BBC News 2004 Dec 9

HSL48
Mangan K.
Medical Association Calls for End to Confidentiality Demands by Research Sponsors
The Chronicle of Higher Education 2004 Dec 9

HSL50
FDA Warns Heart-Bypass Patients Shouldn't Take Painkiller Bextra
The Wall Street Journal 2004 Dec 9

HSL51
Drug Maker Withheld Paxil Study Data: ABC News Uncovers Documents Unknown to Regulators and Many Doctors
ABC News 2004 Dec 9

HSL53
Carroll J.
Extreme Disease Deficit
San Francisco Chronicle 2004 Dec 8

HSL778
Metherell M.
New deadline for medicine costs pledge
Sydney Morning Heral 2004 Dec 8

HSL22
Boseley S.
Antidepressant pills 'too readily prescribed': Medicines regulator decides there is no evidence drugs cause increased self harm but inquiry criticised for not seeing full trial data
2004 Dec 7

HSL23
Vedantam S.
British Officials Advise Less Use of Antidepressants
The Washington Post 2004 Dec 7

HSL11543
Angell M.
Excess in the pharmaceutical industry.
CMAJ 2004 Dec 7; 171:(12):1451-3
http://www.cmaj.ca/cgi/content/full/171/12/1451

HSL20
Harris G.
At F.D.A., Strong Drug Ties and Less Monitoring
The New York Times 2004 Dec 6

HSL21
Boseley S.
Antidepressants to be ruled safe: Watchdog criticised for today's announcement
The Guardian 2004 Dec 6

HSL24
Hale V.
Creating More Paths to Hope
Newsweek 2004 Dec 6

HSL45
McCoy K.
Drugmaker rebuffed call to monitor users
USA TODAY 2004 Dec 6

HSL46
Britain overdoses on anti-depressants
The Daily Mail 2004 Dec 6

HSL355
Jureidini J, Tonkin A, Mansfield PR.
TADS study raises concerns.
BMJ 2004 Dec 4; 329:(7478):1343-4
http://bmj.bmjjournals.com/cgi/content/full/329/7478/1343-d

HSL67
Hirschler B.
Britain May Tighten Rules on Antidepressant Drugs
Reuters 2004 Dec 3

HSL19852
Limprecht E
RACGP fundraiser ethics questioned
Australian Doctor 2004 Dec 3
http://www.australiandoctor.com.au/news/racgp-fundraiser-ethics-questioned

HSL1639
Finucane TE, Boult CE.
Association of funding and findings of pharmaceutical research at a meeting of a medical professional society.
Am J Med 2004 Dec 1; 117:(11):842-5
http://linkinghub.elsevier.com/retrieve/pii/S0002-9343(04)00583-2

HSL1890
Fitzgerald MA.
Appropriate antibiotic prescribing. Guidance for the use of drug samples
Adv Nurse Pract. 2004 Dec 01; 12:(12):18-22

HSL5304
Muijrers PE, Janknegt R, Sijbrandij J, Grol RP, Knottnerus JA.
Prescribing indicators. Development and validation of guideline-based prescribing indicators as an instrument to measure the variation in the prescribing behaviour of general practitioners.
Eur J Clin Pharmacol 2004 Dec 01; 60:(10):739-46
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3055&uid=15517226&db=PubMed&url=http://dx.doi.org/10.1007/s00228-004-0821-5

HSL5333
Fontanarosa PB, Rennie D, DeAngelis CD.
Postmarketing surveillance--lack of vigilance, lack of trust.
JAMA 2004 Dec 1; 292:(21):2647-50
http://jama.ama-assn.org/cgi/content/full/292/21/2647

HSL5347
Lichtenberg P, Heresco-Levy U, Nitzan U.
The ethics of the placebo in clinical practice.
J Med Ethics 2004 Dec 01; 30:(6):551-4
http://jmp.oxfordjournals.org/content/31/1/65.abstract

HSL353
Light DW, Lexchin J.
Will lower drug prices jeopardize drug research? A policy fact sheet
Am J Bioeth 2004 Winter; 4:(1):1-4
http://bioethics.net/journal/j_articles.php?aid=61

HSL1615
Douglas KM, Sutton RM.
Right about others, wrong about ourselves? Actual and perceived self-other differences in resistance to persuasion
Br J Soc Psychol 2004 Dec; 43:(Pt 4):585-603
http://www.ingentaconnect.com/content/bpsoc/bjsp/2004/00000043/00000004/art00007?token=005c10cc4e7247444f6d6222346b62687633502b333e3541333c4a2f246c6a38574b675423783c77eefc266e7e60

HSL1641
Waack KE, Ernst ME, Graber MA.
Informational content of official pharmaceutical industry web sites about treatments for erectile dysfunction.
Ann Pharmacother 2004 Dec; 38:(12):2029-34
http://www.theannals.com/cgi/content/full/38/12/2029

HSL1642
Donohue JM, Berndt ER, Rosenthal M, Epstein AM, Frank RG.
Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression.
Med Care 2004 Dec; 42:(12):1176-85
http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0025-7079&volume=42&issue=12&spage=1176

HSL4893
Caplan A, Elliott C.
Is it ethical to use enhancement technologies to make us better than well?
PLoS Med 2004 Dec; 1:(3):e52
http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed&pubmedid=15630464

HSL4895
Turner EH.
A taxpayer-funded clinical trials registry and results database.
PLoS Med 2004 Dec; 1:(3):e60
http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed&pubmedid=15562322

HSL19388
Mizik N, Jacobson R
Are physicians 'easy marks'? quantifying the effects of detailing and sampling on new prescriptions
Management Science 2004 Dec; 50:(12):
http://portal.acm.org/citation.cfm?id=1045853

HSL20131
CHSRF
Myth: Direct-to-consumer advertising is educational for patients
Mythbusters 2004 Dec;
http://jhsrp.rsmjournals.com/content/11/3/189.citation

HSL719
Meier B .
The Academic Connection: Contracts Keep Drug Research Out of Reach
The New York Times 2004 Nov 29

HSL1643
Food and Drug Administration, HHS.
Drug labeling; sodium labeling for over-the-counter drugs.
Federal Register 2004 Nov 29; 69:(228):
http://a257.g.akamaitech.net/7/257/2422/06jun20041800/edocket.access.gpo.gov/2004/pdf/04-26269.pdf

HSL7452
Carey J, Barrett A, Cropper CM.
Lessons From The Vioxx Fiasco : What drugmakers, the FDA, doctors, and patients need to do
Business Week 2004 Nov 29
http://www.businessweek.com/magazine/content/04_48/b3910055_mz011.htm?chan=search

HSL7982
Zarembo A.
Bayer Held Back on Drug Dangers
Los Angeles Times 2004 Nov 23A12
http://pqasb.pqarchiver.com/latimes/access/741574781.html?dids=741574781:741574781&FMT=ABS&FMTS=ABS:FT&type=current&date=Nov+23%2C+2004&author=Alan+Zarembo&pub=Los+Angeles+Times&edition=&startpage=A.12&desc=The+Nation

HSL19829
Lexchin J, Mintzes B
Transparency in drug regulation: Mirage or oasis?
CMAJ 2004 Nov 23; 171:(11):1363-5
http://www.cmaj.ca/content/171/11/1363

HSL724
Santini , L .
Drug Companies Look to China For Cheap R&D
THE WALL STREET JOURNAL 2004 Nov 22

HSL1173
L-carnitine
Med Lett Drugs Ther 2004 Nov 22; 46:(1196):95-6

HSL770
How the drug cartel thrives
Sunday Herald 2004 Nov 21

HSL135
Drug companies blinded by quest for profit
Montreal Gazette 2004 Nov 19

HSL136
Liberal's plan to get discount medicines to poor nations panned
Globe and Mail 2004 Nov 19

HSL5381
United States Senate Committee on Finance Web page
Testimony of David J. Graham, MD, MPH
: United States Senate Committee on Finance Web page 2004 Nov 18
http://finance.senate.gov/hearings/testimony/2004test/111804dgtest.pdf

HSL4447
Mansfield PR.
Safety Query.
Australian Doctor Weekly 2004 Nov 17

HSL17369
Sedgman J
GPs seek right to give drug info to pharmaceutical firms
PM : ABC Radio National 2004 Nov 17
http://www.abc.net.au/pm/content/2004/s1245798.htm

HSL133
Proposal will save health cash: MP
Windsor Star 2004 Nov 15

HSL5285
Langton PE, Hankey GJ, Eikelboom JW.
Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions: we need processes in place to follow up suspicions about serious adverse events.
Med J Aust 2004 Nov 15; 181:(10):524-5
http://www.mja.com.au/public/issues/181_10_151104/lan10728_fm.html

HSL11539
Anand G.
How Drugs for Rare Diseases Became Lifeline for Companies
The Wall Street Journal 2004 Nov 15A1
http://online.wsj.com/article/SB113202332063297223.html?mod=yahoo_hs&ru=yahoo

HSL19948
Limprecht E
GPs paid peanuts for data
Australian Doctor 2004 Nov 121
http://www.australiandoctor.com.au/news/gps-paid-peanuts-for-data

HSL19949
Burge K
Data sales risk patient trust
Medical Observer 2004 Nov 129
http://www.rheumatologyupdate.com.au/news/data-sales-risk-patient-trust---mo-news

HSL19957
Borland J
Copyright-sharing group delves into science
CNet News.com 2004 Nov 10
http://news.cnet.com/2100-1025_3-5447531.html

HSL1794
Abraham J.
Pharmaceuticals, the state and the global harmonisation process.
Aust Health Rev 2004 Nov 8; 28:(2):150-60
http://www.aushealthreview.com.au/publications/articles/issues/ahr_28_2_081104/ahr_28_2_150-160.asp

HSL764
Moran , M .
AMA to Study Safety of SSRIs In Youngsters
Psychiatric News 2004 Nov 5

HSL19955
Limprecht E
'Toe tag' ad stirs more debate
Australian Doctor 2004 Nov 3
http://www.australiandoctor.com.au/news/--8216;toe-tag--8217;-ad-stirs-more-debate

HSL1827
Bellin M, McCarthy S, Drevlow L, Pierach C.
Medical students' exposure to pharmaceutical industry marketing: a survey at one U.S. medical school.
Acad Med. 2004 Nov;79(11):1041-5. 2004 Nov 01; 79:(11):1041-5
http://www.academicmedicine.org/cgi/content/full/79/11/1041

HSL5417
Dybdahl T, Andersen M, Sondergaard J, Kragstrup J, Kristiansen IS.
Does the early adopter of drugs exist ? A population-based study of general practitioners' prescribing of new drugs.
Eur J Clin Pharmacol 2004 Nov 01; 60:(9):667-72
http://www.springerlink.com/(qwbstlvsg40bdiuu3sqlkg45)/app/home/contribution.asp?referrer=parent&backto=issue,9,12;journal,24,394;linkingpublicationresults,1:100413,1

HSL17368
Wilde Mathews A, Martinez B
Warning Signs: E-Mails Suggest Merck Knew Vioxx's Dangers at Early Stage As Heart-Risk Evidence Rose, Officials Played Hardball; Internal Message: 'Dodge!'
The Wall Street Journal 2004 Nov 1
http://www.marshall-attorneys.com/Press/2004_11_01_WSJ.htm

HSL285
Allen K, Mansfield P.
Changing attitudes to 'the change'.
Aust Fam Physician 2004 Nov; 33:(11):939-40
http://www.racgp.org.au/document.asp?id=15004

HSL354
Mansfield PR, Henry D.
Misleading drug promotion--no sign of improvements.
Pharmacoepidemiol Drug Saf 2004 Nov; 13:(11):797-9
http://www3.interscience.wiley.com/cgi-bin/abstract/107632790/ABSTRACT

HSL1153
Wazana A, Granich A, Primeau F, Bhanji NH, Jalbert M.
Using the literature in developing McGill's guidelines for interactions between residents and the pharmaceutical industry.
Acad Med 2004 Nov; 79:(11):1033-40
http://www.academicmedicine.org/cgi/content/full/79/11/1033

HSL1458
Lankinen KS, Levola T, Marttinen K, Puumalainen I, Helin-Salmivaara A.
Industry guidelines, laws and regulations ignored: quality of drug advertising in medical journals.
Pharmacoepidemiol Drug Saf 2004 Nov; 13:(11):789-95
http://www3.interscience.wiley.com/cgi-bin/abstract/109712611/ABSTRACT

HSL1780
Brownfield ED, Bernhardt JM, Phan JL, Williams MV, Parker RM.
Direct-to-consumer drug advertisements on network television: an exploration of quantity, frequency, and placement.
J Health Commun 2004 Nov-Dec; 9:(6):491-7
http://www.ncbi.nlm.nih.gov/pubmed/15764448

HSL1791
Ahmed SB, Grace SL, Stelfox HT, Tomlinson G, Cheung AM.
Gender bias in cardiovascular advertisements.
J Eval Clin Pract 2004 Nov; 10:(4):531-8
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2753.2003.00483.x

HSL1792
Ahmed SB, Grace SL, Stelfox HT, Tomlinson G, Cheung AM.
Portrayal of female physicians in cardiovascular advertisements.
Can J Cardiol 2004 Nov; 20:(13):1351-4

HSL1793
Agrawal S, Saluja I, Kaczorowski J.
A prospective before-and-after trial of an educational intervention about pharmaceutical marketing.
Acad Med 2004 Nov; 79:(11):1046-50
http://www.academicmedicine.org/cgi/content/full/79/11/1046

HSL1885
O'Donnell MJ, Molloy DW, Smith SD, Dubois S, Russo RM.
The self-perceived role and educational needs of pharmaceutical representatives: a survey.
Educ Health (Abingdon) 2004 Nov; 17:(3):339-45

HSL1886
Huh J, Cude BJ.
Is the information
J Health Commun 2004 Nov-Dec; 9:(6):529-40
http://www.ncbi.nlm.nih.gov/pubmed/15764451

HSL4894
Moynihan R.
The intangible magic of celebrity marketing.
PLoS Med 2004 Nov; 1:(2):e42
http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed&pubmedid=15578110

HSL20047
Metzl JM, Howell JD
Making History: Lessons from the Great Moments Series of Pharmaceutical Advertisements
Academic Medicine 2004 Nov; 79:(11):1027-1032
http://journals.lww.com/academicmedicine/fulltext/2004/11000/making_history__lessons_from_the_great_moments.3.aspx

HSL366
Sweet M.
Doctors and drug companies are locked in 'vicious circle'.
BMJ 2004 Oct 30; 329:(7473):998
http://bmj.bmjjournals.com/cgi/content/full/329/7473/998

HSL5472
Mansfield PR.
Reform of incentives would help reduce harm from drug promotion
BMJ 2004 Oct 30; 329:
http://bmj.bmjjournals.com/cgi/eletters/329/7473/998

HSL12191
Gabbay J, le May A.
Evidence based guidelines or collectively constructed "mindlines?" Ethnographic study of knowledge management in primary care
BMJ 2004 Oct 30; 329:(7473):1013
http://www.bmj.com/cgi/content/full/329/7473/1013

HSL19842
Hungerford C
Insulting ad
Australian Doctor 2004 Oct 2925

HSL15712
Blumenthal D.
Doctors and drug companies.
N Engl J Med. 2004 Oct 28; 351:(18):1885-90
http://content.nejm.org/cgi/content/extract/351/18/1885

HSL19512
Studdert DM, Mello MM, Brennan TA
Financial conflicts of interest in physician relationships with pharmaceutical companies--self regulation in the shadow of federal prosecution.
NEJM 2004 Oct 28; 351:1891-1900
http://www.nejm.org/doi/full/10.1056/NEJMlim042229

HSL19741
Ed.
The mechanics of marketing ROI
eyeforpharma.com 2004 Oct 28
http://social.eyeforpharma.com/uncategorised/mechanics-marketing-roi

HSL995
Ranald P.
A clear choice: abandon or defend FTA
Australian Financial Review 2004 Oct 22

HSL994
Davidson K.
Can we please get serious?: The US free trade deal may be a disaster for Australia. Not that our politicians seem to care
The Age 2004 Oct 21

HSL1891
Aasland OG, Forde R.
[Physicians and drug industry: attitudes and practice].
Tidsskr Nor Laegeforen 2004 10 21; 124:(20):2603-6
http://www.tidsskriftet.no/pls/lts/pa_lt.visSeksjon?vp_SEKS_ID=1083681

HSL3679
Topol EJ.
Failing the public health--rofecoxib, Merck, and the FDA.
N Engl J Med 2004 Oct 21; 351:(17):1707-9
http://content.nejm.org/cgi/content/extract/351/17/1707

HSL5422
Fitzgerald GA.
Coxibs and cardiovascular disease.
N Engl J Med 2004 Oct 21; 351:(17):1709-11
http://content.nejm.org/cgi/content/extract/351/17/1709

HSL20240
Taylor RS, Drummond MF, Salkeld G, Sullivan SD
Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle
BMJ 2004 Oct 21;
http://www.bmj.com/content/329/7472/972.full

HSL992
Hensley S, Hollister H.
Pfizer Reports Solid Earnings;Wyeth Returns to Profitability Restrained Drug-Price Rise May Slow Growth
Wall Street Journal 2004 Oct 20

HSL993
Mitchell A.
PBS faces winds of change
Australian Financial Review 2004 Oct 20

HSL990
Pollack A.
A New Trial of Celebrex, and Questions on Its Timing
The New York Times 2004 Oct 19

HSL991
Hensley S.
FDA Says It Is Too Soon to Tell If Vioxx's Risks Apply to Class Merck's Recall Decision Raises Safety Questions In Similar Arthritis Drugs
Wall Street Journal 2004 Oct 19

HSL958
Gladwell M.
High Prices: How to think about prescription drugs.
The New Yorker 2004 Oct 18

Page 111 of 144 pages ‹ First  < 109 110 111 112 113 >  Last ›